Abstract
The finding that IgM-rheumatoid factor and anti-cyclic citrullinated peptide were present in stored blood samples in a significant number of patients with rheumatoid arthritis years before the manifestation of the disease, suggests the disease has a long pre-clinical phase. It might thus be possible to prevent clinical disease by initiating treatment in this pre-clinical phase. Recently a Dutch clinical trial was started with this objective. Patients at risk will be randomised to receive dexamethasone or placebo treatment.
MeSH terms
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use
-
Arthritis, Rheumatoid / diagnosis*
-
Arthritis, Rheumatoid / prevention & control
-
Autoantibodies / blood*
-
Citrulline / immunology*
-
Dexamethasone / administration & dosage
-
Dexamethasone / therapeutic use
-
Humans
-
Immunoglobulin M / blood
-
Netherlands
-
Rheumatoid Factor / blood*
-
Risk Factors
-
Sensitivity and Specificity
-
Time Factors
Substances
-
Anti-Inflammatory Agents
-
Autoantibodies
-
Immunoglobulin M
-
Citrulline
-
Dexamethasone
-
Rheumatoid Factor